Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Valeant cuts revenue forecast; makes progress on debt repayment

Canada's Valeant Pharmaceuticals cut its full-year revenue forecast, even as it reported a better-than-expected quarterly profit and said it expects to repay more than $5 billion in debt by February.

Since taking the helm in April 2016, Joseph Papa has been trying to rebuild the company's business and regain investor confidence after a flurry of investigations into its accounting and pricing practices.

One of Papa's biggest challenges has been to cut the company's towering debt, which ballooned to nearly $30 billion following a spate of deal-making under former CEO Mike Pearson.

Excluding items, the Laval, Quebec-based company earned $1.05 per share, ahead of the average analyst estimate of 94 cents, according to Thomson Reuters I/B/E/S.

Revenue fell 7.8 percent to $2.23 billion in the second quarter ended June 30, hurt by declines in volume and pricing of its generic and neurology products.


  • Valeant quarterly revenue falls 8%BNN
  • What's Valeant Pharmaceuticals Internat (NYSE:VRX) Upside After This Short ...BZ Weekly
  • Valeant Pharmaceuticals (VRX) Stock: Gaining On Earnings And RumorsCNA Finance (press release)
  • Valeant: Why Teva's Blowup Could Be Good NewsBarron's
  • Valeant reduces Q2 loss, revenue falls amid divestmentsMetroNews Canada
  • Valeant Q2 top line down 8%; non-GAAP earnings down 21%; cash flow down 40 ...Seeking Alpha
  • Rafferty Asset Management Lifted Intel (INTC) Stake by $650700; Hexavest Has ...BZ Weekly
  • Valeant Pharmaceuticals International Inc. - Receive News & Ratings DailyBNB Daily (blog)
  • BTIG Reconfirms a Hold Rating on Valeant Pharma (VRX); First Foundation Inc

This post first appeared on The 5th News, please read the originial post: here

Share the post

Valeant cuts revenue forecast; makes progress on debt repayment


Subscribe to The 5th News

Get updates delivered right to your inbox!

Thank you for your subscription